U.S. Markets closed

TransMedics to Report Third Quarter 2019 Financial Results on November 6, 2019

ANDOVER, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter of 2019 after market close on Wednesday, November 6, 2019. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (866) 221-1172 for domestic callers or (270) 215-9603 for international callers, followed by Conference ID: 5969739. A live and archived webcast of the event will be available on the “Investors” section of the TransMedics website at www.transmedics.com

About TransMedics Group, Inc.

TransMedics is the world’s leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.

Investor Contact:
Greg Chodaczek or Lynn Lewis
646-924-1769
Investors@transmedics.com